Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

NCT: NCT06168942 · SUSPENDED

NCT IDNCT06168942
StatusSUSPENDED
Start Date2024-02-19
Completion2032-02-29
SponsorJaguar LAA, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial fibrillation (NVAF) to reduce the risk of stroke (blocked blood vessel or bleeding in brain) and systemic embolism (blockage in a blood vessel harming vital organs).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑